Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.53
    -0.01 (-1.40%)

    Market Cap: $14.69M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Citius Pharmaceuticals Inc (CTXR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Citius Pharmaceuticals (CTXR) trades at 1.9x sales and 0.2x book value. Its P/B of 0.2x is below its 5-year median of 1.2x. Its forward P/E is 0.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E0.3x
    Price to sales1.9x
    Price to book0.2x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 85.7% below 1.4x.

    MultipleCurrent5-year median10-year median
    P/B0.2x1.2x1.4x
    Medians of month-end values through Oct 2026: 59 months (5-year) and 111 months (10-year).

    Valuation History

    Over the 9 year ends shown, its P/B ranged from 0.2x in 2025 to 31.6x in 2017. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$0.784.2x0.2x
    2024$4.00N/A0.5x
    2023$18.91N/A1.4x
    2022$19.75N/A28.8x
    2021$38.50N/A1.8x
    2020$25.50N/A2.0x
    2019$25.50N/A1.5x
    2018$26.00N/A0.8x
    2017$95.00N/A31.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CTXR

    What is CTXR's forward P/E ratio?

    Citius Pharmaceuticals has a forward P/E ratio of 0.3x.

    Is CTXR stock overvalued?

    GNG's valuation label for CTXR is Undervalued.

    What is CTXR's price to sales ratio?

    Citius Pharmaceuticals has a price to sales ratio of 1.9x.